| Literature DB >> 26931809 |
Marta G Novelle1, Ahmed Ali2, Carlos Diéguez3, Michel Bernier2, Rafael de Cabo2.
Abstract
Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and age-related pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26931809 PMCID: PMC4772077 DOI: 10.1101/cshperspect.a025932
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915